Kristin Abate Biography and Net Worth

Kristin Abate is the CAO of Karyopharm Therapeutics.

What is Kristin Abate's net worth?: The estimated net worth of Kristin Abate is at least $41.74 thousand as of September 1st, 2026. Abate owns 23,782 shares of Karyopharm Therapeutics stock worth more than $41,737 as of September 25th. This net worth estimate does not reflect any other investments that Abate may own. Learn More about Kristin Abate's net worth.
How do I contact Kristin Abate?: The corporate mailing address for Abate and other Karyopharm Therapeutics executives is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. Karyopharm Therapeutics can also be reached via phone at (617) 658-0600 and via email at [email protected]. Learn More on Kristin Abate's contact information.
Has Kristin Abate been buying or selling shares of Karyopharm Therapeutics?: Within the last three months, Kristin Abate has sold $38.38 of Karyopharm Therapeutics stock. Most recently, Kristin Abate sold 19 shares of the business's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $2.02, for a transaction totalling $38.38. Following the completion of the sale, the chief accounting officer now directly owns 23,782 shares of the company's stock, valued at $48,039.64. Learn More on Kristin Abate's trading history.
Who are Karyopharm Therapeutics' active insiders?: Karyopharm Therapeutics' insider roster includes Kristin Abate (CAO), Garen Bohlin (Director), Sohanya Cheng (Chief Commercial Officer and Head of Business Development), Michael Kauffman (Director), Michael Mano (Executive Vice President, Chief Legal Officer and Secretary), Michael Mason (CFO), Stephen Mitchener (SVP), Richard Paulson (President and Chief Executive Officer), Stuart Poulton (Chief Development Officer), Reshma Rangwala (Chief Medical Officer & Head of Research), Sharon Shacham (Insider), and Jatin Shah (EVP). Learn More on Karyopharm Therapeutics' active insiders.
Are insiders buying or selling shares of Karyopharm Therapeutics?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 1,334 shares worth more than $9,605.84. The most recent insider tranaction occured on September, 1st when CAO Kristin Abate sold 19 shares worth more than $38.38. Insiders at Karyopharm Therapeutics own 1.7% of the company. Learn More about insider trades at Karyopharm Therapeutics.
Information on this page was last updated on 9/1/2026.

Kristin Abate Insider Trading History at Karyopharm Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/1/2026	Sell	19	$2.02	$38.38	23,782
1/28/2026	Sell	50	$7.03	$351.50	22,622
1/21/2026	Sell	265	$5.96	$1,579.40	22,580
10/1/2025	Sell	362	$6.30	$2,280.60	10,046
9/15/2025	Sell	23	$6.43	$147.89	10,408
9/3/2025	Sell	12	$6.78	$81.36	9,463
7/22/2025	Sell	238	$4.00	$952.00	9,475

Kristin Abate Buying and Selling Activity at Karyopharm Therapeutics

Karyopharm Therapeutics Company Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $1.75

$1.67

$1.77

50 Day Range

MA: $2.98

$1.54

$9.51

2 Week Range

Now: $1.75

$1.24

$10.99

Volume

521,564 shs

Average Volume

1,022,811 shs

Market Capitalization

$39.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95